End-of-2020 inventory of the most cancer-targeted and immunotherapy drugs in history (including coverage and prices)!

Do you want to fully understand the current domestic and foreign targeted immunotherapy drugs for different types of cancer? Which drugs are available domestically and covered by health insurance? Today, the small editor specifically took out a collection of accumulated treasures to share with you, that is, according to the cancer classification summary covering more than 20 cancer species of targeted immune drugs, involving these drugs listed at home and abroad, NCCN and CSCO guidelines recommended super-drug instructions and medical insurance inclusion and other circumstances (see table below) in this share.
years, the rise of a new generation of anti-tumor drugs has caused the treatment of tumors to leap from the era of cytotoxic drug therapy to a new era of precision targeted therapy based on genetic variation.
After sufficient clinical evidence, molecular targeted treatment can not only accurately "kill tumors", but also can delay the development of tumors, and thus prolong the survival of patients with tumors, so that the clinical treatment objectives of cancer patients gradually turn to the "chronic disease management" state, just as hypertension patients need to continue to take antihypertensive drugs, diabetics need to take anti-sugar drugs, cancer can also be regarded as a special "chronic disease", the need for long-term use of anti-tumor drugs.
In the case of lung cancer, for example, the average survival time for patients with advanced lung cancer used to be only about 10 months;
No.1 immune checkpoint inhibitor No.2 lung cancer No.3 breast cancer No.4 color rectal cancer No.5 stomach cancer No.6 gastrointestinal tumor No.7 bile tube cancer No.8 esophageal cancer No.9 pancreatic cancer No.10 liver cancer No. .11 Conjunctive primary periton cancer bowel cancer No.12 god by the genitourinary no.13 pre-adenocarcinoma No.14 bladder cancer No.15 kidney cancer No.16 cervical cancer No.17 fallopian tube cancer No.18 egg nest cancer No. 19 White blood disease No.20 gonorrhea No.21 multiple bone myeloma No.22 melanoma No.23 Mercer cell cancer No.24 substrate cell cancer No.25 adenocarcinoma No.26 head neck tumor No.26 27 soft group woven sarcoma Karelli pearl single resistance has non-squamous non-small cell lung cancer adaptation, hepatocellular carcinoma second-line adaptation, esophageal squamous cancer second-line adaptation; Liver cancer 2020 has home-made new drugs Donaphini, kidney cancer sorafini, prostate abitron and Nzaruaan.
the following drugs are also covered by health insurance: soraphinib and gregorinib liver cancer; time and drug names are updated as follows: Pfizer's Dacomitinib is on the market in May 2019, Chinese translation of Dacotinib December 2019 The State Drug Administration announced that the two-targeted joint therapeutic drugs applicable to the treatment of BRAF V600 mutation-positive non-excisible or metastasis melanoma, Novartic Tumor's Darafinib (commodity name Tefel) and Qumetini (commodity name Maginen) dual-targeted joint therapy drug have been licensed in China.
new drug Herssele (generic name: Enmetro-Zhu single resistance) on the market! This is the first antibody conjugate drug approved in China (english name Antibody-drug Conjugate, abbreviated as ADC).
in February 2020, Roche's PDL1 monoantigen was launched in February 2020, with symptoms of small cell lung cancer and hepatocellular carcinoma.
Avelumab is from Merck, Germany, not Merca East.
carelli's single anti-phobias: lung, esophageal and liver cancer.
apatini to increase stomach cancer adaptation.
above, AstraZeneta's "Devalu Mono-Resistance" in China has been listed, the name has been corrected to "Dvali-Yu single-resistance".
。